Evan Owens

Mr. Evan Owens

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Translational Andrology and Urology
Verified
Journal Article
Closed access
PDF file
EOEvan Owens
Evan Owens
David VeseyDavid Vesey
David Vesey
AKAndrew Kassianos
Andrew Kassianos
HHHelen G. Healy
Helen G. Healy
WHWendy E. Hoy
Wendy E. Hoy
GGGlenda C. Gobe
Glenda C. Gobe
Chronic kidney disease (CKD) is a clinical syndrome with many adverse sequelae and is currently a major global health and economic burden. Regardless of aetiology, inflammation and fibrosis are common manifestations of CKD. Unfortunately, the underlying pathophysiological mechanisms are poorly understood, and robust prognostic and early diagnostic biomarkers of CKD are lacking. One immune cell population that has received little attention in the context of CKD is mast cells (MCs). This mini review will examine the role of MCs as facilitators of kidney inflammation and fibrosis, propose a mechanistic structure for MCs in CKD, and give consideration to biomarkers specific for MC activation that can be deployed clinically. MCs are derived from haematopoietic stem cells. They are characterised by electron-dense granules in the cytoplasm, filled with preformed mediators. MCs can synthesise a range of bio-active compounds. Activation of MCs modulates an innate immune and adaptive effector response. Increased MC counts have been observed in animal models of kidney disease and a range of kidney diseases in humans where MC presence has been linked to biomarkers of kidney function and tissue damage. To further implicate MCs in CKD, several chemokines, cytokines and proteases released by MCs have been observed in their own right in various kidney diseases and linked to progressive CKD. One compound released by MCs that is of particular interest is the MC-specific protease tryptase. This protease is capable of activating the G-protein coupled receptor (GPCR) protease activated receptor-2 (PAR-2). PAR-2 is widely expressed throughout the kidney and highly expressed in the tubular epithelial cells where its activation induces robust inflammatory and fibrotic responses. Novel prognostic and diagnostic biomarkers of CKD are needed. MC-specific proteases [tryptase, chymase and carboxypeptidase A3 (CPA3)] are easily detectable in the blood but questionably in the urine. This review aims to promote these as prognostic and diagnostic biomarkers in the context of CKD.

14 December 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
EOEvan Owens
Evan Owens
TKTan Ken-Soon
Tan Ken-Soon
RERobert Ellis
Robert Ellis
SVSharon Del Vecchio
Sharon Del Vecchio
THTyrone Humphries
Tyrone Humphries
GGGlenda Gobe
Glenda Gobe
Chronic kidney disease (CKD) patients typically progress to kidney failure, but the rate of progression differs per patient or may not occur at all. Current CKD screening methods are sub-optimal at predicting progressive kidney function decline. This investigation develops a model for predicting progressive CKD based on a panel of biomarkers representing the pathophysiological processes of CKD, kidney function, and common CKD comorbidities. Two patient cohorts are utilised: The CKD Queensland Registry (n = 418), termed the Biomarker Discovery cohort; and the CKD Biobank (n = 62), termed the Predictive Model cohort. Progression status is assigned with a composite outcome of a ≥30% decline in eGFR from baseline, initiation of dialysis, or kidney transplantation. Baseline biomarker measurements are compared between progressive and non-progressive patients via logistic regression. In the Biomarker Discovery cohort, 13 biomarkers differed significantly between progressive and non-progressive patients, while 10 differed in the Predictive Model cohort. From this, a predictive model, based on a biomarker panel of serum creatinine, osteopontin, tryptase, urea, and eGFR, was calculated via linear discriminant analysis. This model has an accuracy of 84.3% when predicting future progressive CKD at baseline, greater than eGFR (66.1%), sCr (67.7%), albuminuria (53.2%), or albumin-creatinine ratio (53.2%).

6 May 2019 in Open Journal of Bioresources
Verified
Journal Article
Open access
PDF file
EOEvan Owens
Evan Owens
WHWendy E Hoy
Wendy E Hoy
ACAnne Cameron
Anne Cameron
JCJeff Coombes
Jeff Coombes
GGGlenda Gobe
Glenda Gobe
The Chronic Kidney Disease (CKD) Biobank is a repository for plasma, erythrocytes, serum, peripheral blood mononuclear cells (PBMCs), DNA, kidney core biopsies, and relevant clinical data. These materials are collected from CKD patients and healthy controls in Queensland, Australia. Plasma, erythrocytes, serum, urine, and PBMCs are collected annually; DNA and kidney core biopsies are one-off collections; and clinical data are updated annually. The CKD Biobank aims to provide domestic investigators associated with the CKD Centre of Research Excellence (CKD.QLD), and international investigators of CKD, with a resource to support future research to improve clinical outcomes of CKD patients. Funding statement: The National Health and Medical Research Council Centres of Research Excellence scheme and the University of Queensland’s Simple Procurement Plan currently fund the CKD Biobank.